Trial
NCT05810961
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
argenx
Collaborators
Zai Lab Pty. Ltd.
Condition
Membranous Nephropathy
Intervention
efgartigimod IV
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-22